NCT00920205View on ClinicalTrials.gov

Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Cancer
Interventions
DRUG

MPC-3100 (an Hsp90 inhibitor)

oral daily dose for 21 days in a 28-day cycle

Trial Locations (3)

19111

Fox Chase Cancer Center, Philadelphia

78229

South Texas Accelerated Research Therapeutics, San Antonio

89135

Nevada Cancer Institute, Las Vegas

Sponsors

Lead Sponsor

Myrexis Inc.
All Listed Sponsors
lead

Myrexis Inc.

INDUSTRY

NCT00920205 - Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments | Biotech Hunter | Biotech Hunter